inSIGNALS Neurotech

inSignals Neurotech operates at the intersection of neuroscience, digital health, wearable monitoring, and clinical decision support. Its stated focus is Parkinson’s disease, where it aims to quantify motor symptoms outside conventional episodic assessments and translate movement data into information clinicians can use. The described iHandU product targets rigidity, tremor, bradykinesia, and gait abnormalities; its Apple Watch approach is intended to support continuous monitoring in patients’ daily lives. The company also describes predictive analysis of motor fluctuations and OFF episodes as a development focus, extending its proposition beyond measurement toward treatment support. Its origins as an INESC TEC spin-off connect the business to an R&D environment, while its disclosed seed funding—$121,322 from Portugal Ventures in 2021—indicates an early-stage scale relative to established digital-health businesses.

The company’s trajectory reflects a research-to-market transition rather than a documented sequence of large financing or expansion milestones. It was founded in 2019 to commercialize solutions developed by the INESC TEC research group, and iHandU was identified as its first product for assessing motor rigidity and supporting deep brain stimulation therapy for people with Parkinson’s disease. Product descriptions now encompass assessment of rigidity, tremor, bradykinesia, and gait, while the company’s Apple Watch and AI approach adds a path toward continuous and remote monitoring. Predictive models for motor fluctuations and OFF episodes are described as under development, marking a potential move from symptom measurement toward proactive clinical support, not a confirmed commercial launch. The employee range is 1–10, with no hiring announcement or later financing milestone available.